CASI Pharmaceuticals Stock Forward View - Double Exponential Smoothing
| CASI Stock | USD 0.21 -0.09 -30.00% |
News-driven analysis for CASI Pharmaceuticals seeks to separate meaningful signals from market noise. By filtering relevant headlines and sentiment trends, this module identifies potential catalysts that may move CASI Pharmaceuticals' price.
At the latest evaluation, CASI Pharmaceuticals shows the 14-period RSI at 24, aligning with traditional oversold thresholds. Values below 30 typically indicate extended downward momentum relative to recent price action.Momentum 24
Sell Stretched
Oversold | Overbought |
EPS Estimate Next Quarter -0.37 | EPS Estimate Current Year -2.58 | EPS Estimate Next Year -1.41 | Wall Street Target Price 4 | Quarterly Revenue Growth -0.60 |
The hype-based summary links CASI Pharmaceuticals attention patterns with price response and peers. This module tracks sentiment for CASI Pharmaceuticals using options positioning and short interest signals.
Comprehensive financial disclosures appear in Dividend Yield and Price To Sales Ratio.
CASI Pharmaceuticals Implied Volatility | 2.92 |
CASI Pharmaceuticals' implied volatility tends to be mean-reverting. Periods of extremely high implied volatility in CASI Pharmaceuticals options are often followed by a contraction as uncertainty resolves, eroding the value of recently purchased options.
The Double Exponential Smoothing forecasted value of CASI Pharmaceuticals on the next trading day is projected to be 0.13 with a mean absolute deviation of 0.04 and the sum of the absolute errors of 2.64.CASI Pharmaceuticals after-hype prediction price | USD 0.21 |
Attention metrics here are presented with forecasting, technical, analyst, and earnings context.
Trending Equities provides context for diversified portfolio design. Such insight adds context to allocation decisions within a diversified portfolio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.CASI Open Interest: 2026-04-17 Options
Open interest for CASI Pharmaceuticals describes outstanding contracts and gives a view of market engagement.
CASI Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine CASI price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for CASI using various technical indicators. When you analyze CASI charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
CASI Pharmaceuticals Double Exponential Smoothing Price Forecast For the 10th of March
Given 90 days horizon, the Double Exponential Smoothing forecasted value of CASI Pharmaceuticals on the next trading day is expected to be 0.13 with a mean absolute deviation of 0.04 , mean absolute percentage error of 0.01 , and the sum of the absolute errors of 2.64 .Please note that although there have been many attempts to predict CASI Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that CASI Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
CASI Pharmaceuticals Stock Forecast Pattern
| Backtest CASI Pharmaceuticals | CASI Pharmaceuticals Price Prediction | Research Analysis |
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Double Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of CASI Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent CASI Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | 0.001 |
| MAD | Mean absolute deviation | 0.0448 |
| MAPE | Mean absolute percentage error | 0.0875 |
| SAE | Sum of the absolute errors | 2.6404 |
Mean reversion in CASI Pharmaceuticals' is more reliable over longer time horizons. Short-term deviations can persist and even widen before correcting, making position sizing and risk management critical.
CASI Pharmaceuticals After-Hype Price Density Analysis
Investors who rely solely on expected value estimates for CASI Pharmaceuticals miss the full picture. CASI Pharmaceuticals' probability distribution reveals that expected value can be achieved through very different combinations of outcomes, each with different risk implications.
Next price density |
| Expected price to next headline |
CASI Pharmaceuticals Estimiated After-Hype Price Volatility
The after-news price analysis for CASI Pharmaceuticals is built on the observation that CASI Pharmaceuticals' market reactions to news are not random but follow recognizable patterns. CASI Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.19 and 0.21, respectively. Identifying and quantifying these patterns for CASI Pharmaceuticals is the core purpose of this model.
Current Value
The after-hype framework applied to CASI Pharmaceuticals assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
CASI Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as CASI Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CASI Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with CASI Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 8 Events | 6 Events | In 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.21 | 0.21 | 0.00 |
|
CASI Pharmaceuticals Hype Timeline
CASI Pharmaceuticals is currently traded for 0.21. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. CASI is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is projected to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on CASI Pharmaceuticals is about 0.0%, with the expected price after the next announcement by competition of 0.21. About 87.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.02. CASI Pharmaceuticals had not issued any dividends in recent years. The entity completed a 1:10 stock split on 2nd of June 2022. Given the investment horizon of 90 days the next projected press release will be in 8 days. Trending Equities provides context for diversified portfolio design. Such insight adds context to allocation decisions within a diversified portfolio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.CASI Pharmaceuticals Related Hype Analysis
The information ratio and semi-deviation metrics in the peer comparison table for CASI Pharmaceuticals provide a risk-adjusted view of how efficiently CASI Pharmaceuticals' competitors convert news exposure into returns relative to downside risk.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CLSD | Clearside Biomedical | 0.36 | 6 per month | 0.00 | -0.27 | 7.96 | -17.54 | 83.67 | |
| CING | Cingulate | 0.02 | 5 per month | 3.89 | 0.19 | 8.45 | -6.53 | 24.88 | |
| ENTO | Entero Therapeutics | 0.09 | 5 per month | 0.00 | -0.01 | 16.86 | -17.06 | 39.61 | |
| CRIS | Curis Inc | -0.04 | 8 per month | 0.00 | -0.05 | 8.00 | -7.83 | 24.00 | |
| PTHS | Pelthos Therapeutics | 1.72 | 6 per month | 0.00 | -0.01 | 12.77 | -8.35 | 24.67 | |
| NCNA | NuCana PLC | -0.23 | 7 per month | 0.00 | -0.20 | 6.22 | -7.98 | 19.15 | |
| PALI | Palisade Bio | -0.13 | 10 per month | 0.00 | -0.0029 | 11.18 | -8.57 | 31.35 | |
| ALLR | Allarity Therapeutics | -0.07 | 5 per month | 4.30 | 0.02 | 8.43 | -7.29 | 29.05 | |
| KAPA | Kairos Pharma | -0.09 | 6 per month | 0.00 | -0.05 | 10.26 | -8.24 | 29.57 | |
| LSTA | Lisata Therapeutics | 0.11 | 12 per month | 1.49 | 0.14 | 6.83 | -3.90 | 93.60 |
CASI Pharmaceuticals Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CASI Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of CASI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing CASI Pharmaceuticals by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
CASI Pharmaceuticals Market Strength Events
Market strength indicators for CASI Pharmaceuticals provide investors with a view of how the stock performs across different market environments. By analyzing these indicators, traders can determine the best moments to enter or exit positions in CASI Pharmaceuticals.
CASI Pharmaceuticals Risk Indicators
A structured analysis of CASI Pharmaceuticals' risk indicators is one of the most reliable ways to improve the accuracy of price forecasts. Understanding the risk embedded in CASI Pharmaceuticals' allows investors to decide whether to accept, reduce, or hedge their exposure.
| Mean Deviation | 4.97 | |||
| Standard Deviation | 10.74 | |||
| Variance | 115.31 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for CASI Pharmaceuticals
Coverage intensity for CASI Pharmaceuticals matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
CASI Pharmaceuticals Short Properties
Short sentiment tied to CASI Pharmaceuticals matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 15.3 M | |
| Cash And Short Term Investments | 16.1 M |
More Resources for CASI Stock Analysis
Reviewing CASI Pharmaceuticals commonly begins with financial statements and performance trends. Ratios and trend metrics help frame CASI Pharmaceuticals' operating context. Outlined below are key reports that provide context for Casi Pharmaceuticals Stock:Trending Equities provides context for diversified portfolio design. Such insight adds context to allocation decisions within a diversified portfolio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Analysis related to CASI Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Earnings Share -3.02 | Revenue Per Share | Quarterly Revenue Growth -0.60 | Return On Assets | Return On Equity |
Investors evaluate CASI Pharmaceuticals using market value and book value, each describing different facets of the business. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Market price can move with sentiment, cycles, and liquidity conditions, so it may drift away from fundamentals. Valuation methods compare these perspectives to frame context.
Value and price for CASI Pharmaceuticals are related but not identical, and they can diverge across cycles. Analysis often considers earnings, revenue quality, fundamentals, technical signals, competition, and analyst coverage. Market price reflects the current exchange level formed by active bids and offers.